Loss of Endocan tumorigenic properties after alternative splicing of exon 2
Open Access
- 18 January 2008
- journal article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 8 (1), 14
- https://doi.org/10.1186/1471-2407-8-14
Abstract
Background: Endocan was originally described as a dermatan sulfate proteoglycan found freely circulating in the blood. Endocan expression confers tumorigenic properties to epithelial cell lines or accelerate the growth of already tumorigenic cells. This molecule is the product of a single gene composed of 3 exons. Previous data showed that endocan mRNA is subject to alternative splicing with possible generation of two protein products. In the present study we identified, and functionally characterized, the alternative spliced product of the endocan gene: the exon 2-deleted endocan, called endocanΔ2.Methods: Stable, endocanΔ2-overexpressing cell lines were generated to investigate the biological activities of this new alternatively spliced product of endocan gene. Tumorigenesis was studied by inoculating endocan and endocanΔ2 expressing cell lines subcutaneously in SCID mice. Biochemical properties of endocan and endocanΔ2 were studied after production of recombinant proteins in various cell lines of human and murine origin.Results: Our results showed that the exon 2 deletion impairs synthesis of the glycan chain, known to be involved in the pro-tumoral effect of endocan. EndocanΔ2 did not promote tumor formation by 293 cells implanted in the skin of severe combined immunodeficient (SCID) mice.Conclusion: Our results emphasize the key role of the polypeptide sequence encoded by the exon 2 of endocan gene in tumorigenesis, and suggest that this sequence could be a target for future therapies against cancer.Keywords
This publication has 30 references indexed in Scilit:
- Endocan Expression and Relationship with Survival in Human Non–Small Cell Lung CancerClinical Cancer Research, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Endocan, a new endothelial marker in human sepsis*Critical Care Medicine, 2006
- Aberrant and Alternative Splicing in CancerCancer Research, 2004
- Molecular mechanisms regulating the tumor-targeting potential of splice-activated gene expressionCancer Gene Therapy, 2004
- Tissue-Wide Expression Profiling Using cDNA Subtraction and Microarrays to Identify Tumor-Specific GenesCancer Research, 2004
- Cloning and Characterization of the Human Lung Endothelial-Cell-Specific Molecule-1 PromoterJournal of Vascular Research, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- Characterization of the Secreted Form of Endothelial-Cell-Specific Molecule 1 by Specific Monoclonal AntibodiesJournal of Vascular Research, 2000
- The Hallmarks of CancerCell, 2000